

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

Investigation into the Inheritance and Biochemistry of Chondrodysplasia in Texel Sheep

A thesis presented in partial fulfilment of the requirements for the
Master of Science
at Massey University,
Palmerston North, New Zealand.

Timothy John Byrne

2005

Acknowledgements

Foremost I would like to express thanks to my supervisors, Professor Hugh Blair, Kathryn Stowell, and Professor Keith Thompson for their continued support and guidance throughout.

Thank you to the scholarship providers including Meat New Zealand and Gisborne Veterinary Club Charitable Trust for their interest in, and support of, the project, and to Palmerston North Medical Research Foundation for their funding.

I would like to acknowledge Graeme Poole and Susan Ellicott for their cooperation and contribution to aspects of the research.

I extend thanks to all the members of my lab-group and office. Those who contributed significantly to whom I would especially like to extend my appreciation include: John Tweedie, Mark Patchett, Rao Dukkupati, Robyn Marston, Carole Flyger, Amram Williams, Kelly Senior, Henning Koehn, Natisha Magan, and Yuliana Yosaatmadja.

Lastly, and most importantly, I would like to thank my family and friends not yet mentioned.

Abstract

A skeletal chondrodysplasia characterized by dwarfism and angular deformity of the forelimbs has been recognized over four seasons in Texel and Texel cross lambs on three related properties. Some affected lambs have normal co-twins indicating that the disease is not dietary, but likely to be the result of a genetic disorder. This study reports on the inheritance and biochemistry of this newly discovered chondrodysplasia in Texel sheep. The outcome of a backcross trial between putative carrier ewes and affected rams provided evidence that indicated that the chondrodysplasia has an autosomal recessive mode of inheritance, and that it is likely to be caused by a single gene defect. Analysis of proteoglycan constituents of cartilage by SDS-PAGE, followed by sulfate-specific staining indicated that the biochemical abnormality lies in the level of sulfation of proteoglycans in the extracellular matrix of affected animals. It was also shown by SDS-PAGE that there were no differences in the major collagen constituents of cartilage between unaffected and affected animals. A candidate gene, the diastrophic dysplasia sulfate transporter, was determined based on its involvement in the process of sulfation of proteoglycans and its involvement in characterized human dysplasias, which resemble Texel chondrodysplasia both phenotypically and biochemically. PCR amplification and sequencing of 85.4 % of this gene revealed no nucleotide differences between the exonic DNA of normal, carrier, and affected animals. While this reduced the likelihood that this gene is causative in the chondrodysplasia, it does not eliminate it as a candidate, based on the fact that a mutation may exist in the region not sequenced, including the possibility of splice site mutations.

Abbreviations

ACG -1B	Achondrogenesis type 1B
AO2	Atelosteogenesis type 2
APS	Adenosine-phosphosulfate
ATP	Adenosine triphosphate
ATPSK2	Adenosine triphosphate sulfurylase/ Adenosine-phosphosulfate kinase 2 gene
bm	Brachymorphic
BSA	Bovine serum albumin
cDNA	Synthetic DNA, generated from RNA
cmd	Cartilage matrix deficiency
COL1	Collagen 1 protein domain
COL2A1	Collagen type II alpha 1 gene
COL3	Collagen 3 protein domain
COL9A1	Collagen type IX alpha 1 gene
COL9A2	Collagen type IX alpha 2 gene
COL9A3	Collagen type IX alpha 3 gene
COL10A1	Collagen type X alpha 1 gene
COL11A1	Collagen type XI alpha 1 gene
COL11A2	Collagen type XI alpha 2 gene
CSPGs	Chondroitin sulfate proteoglycans
DDSH	Dyssegmental dysplasia, Silverman- Handmaker type
Dmm	Disproportionate micromelia
DNA	Deoxyribose Nucleic Acid
dNTP	Deoxynucleoside triphosphate (dATP, dTTP, dCTP, dGTP)
DTDST	Diastrophic dysplasia sulfate transporter
DTT	Dithiothreitol

ECM	Extracellular Matrix
EDTA	Ethylene diamine tetra-acetic acid
FACIT	Fibril- associated with interrupted triple helices
FGFR3	Fibroblast growth factor receptor 3 gene
GAG	Glycosaminoglycan
GCG	Genetics Computer Group
HPLC	High performance liquid chromatography
Hspg2	Heparin sulfate proteoglycan gene 2
MED	Multiple epiphyseal dysplasia
ocd	Osteochondrodysplasia
OSMED	Oto-spondylo-megaepiphyseal dysplasia
PAPS	Phosphoadenosine-phosphosulfate
PCR	Polymerase chain reaction
PMSF	Phenylmethane-sulfonyl fluoride
QTL	Quantitative trait loci
SDSC	San Diego supercomputer center
SDS	Sodium dodecyl sulfate
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SED	Spondyloepiphyseal dysplasia
SEDC	Spondyloepiphyseal dysplasia congenita
SEMD	Spondyloepimetaphyseal dysplasia
SMCD	Schmid metaphyseal chondrodysplasia
SMD	Spondylometaphyseal dysplasia
SJS	Schwartz-Jampel syndrome
SK2	Sulfate kinase 2 gene
TAE	Tris acetate EDTA
TCA	Trichloroacetic acid
TE	Tris –EDTA buffer
UV	Ultra-violet light

List of figures

	Page number
Figure 1: A structural model of aggrecan.	4
Figure 2: Chondrocyte sulfate activation pathway.	11
Figure 3: The collagen II:IX:XI heterofibril.	17
Figure 4: Clinical phenotype of lambs with the Texel Chondrodysplasia.	22
Figure 5: Focal loss of articular cartilage.	23
Figure 6: Transverse sections through the trachea.	24
Figure 7: Haematoxylin and Eosin stained physeal cartilage.	24
Figure 8: Haematoxylin and Eosin stained articular cartilage.	25
Figure 9: Haematoxylin and Eosin stained articular cartilage matrix.	25
Figure 10: Expected outcome from homozygous by carrier cross.	32
Figure 11: BSA standard curve used for determination of protein concentration of collagen and proteoglycan samples.	45
Figure 12: Analysis of collagen in control (C) and affected (A) animals.	47
Figure 13: Analysis of proteoglycans in control (C) and affected (A) animals.	48
Figure 14: Analysis of proteoglycan equal protein loading.	49
Figure 15: Position of PCR and sequencing primers on exon 2.	59
Figure 16: Positioning of PCR and sequencing primers on exon 3.	60
Figure 17: 1% agarose gel showing extracted genomic DNA.	64
Figure 18: 1% agarose gel showing the PCR products from amplification of exon 2.	65
Figure 19: 1% agarose gel showing PCR products from amplification of exon 3.	66
Figure 20: 1% agarose gel showing diagnostic digest of Exon 2 PCR fragment.	67
Figure 21: 1% agarose gel representing quantification of the PCR products of exon 2.	68
Figure 22: 1% agarose gel representing quantification of the PCR products of exon 3.	69
Figure 23: Alignment of the sequenced regions of exon 2.	70
Figure 24: Alignment of the sequenced regions of exon 3.	73
Figure 25: Complete alignment of exon 2 and exon 3 with the complete exonic sequence for the <i>Ovis aries</i> gene encoding sulfate transporter.	76

List of table

	Page number
Table 1: Results (number of offspring in affected and unaffected categories) and chi square analysis of a cross between an affected ram and carrier ewes (Pilot trial year 1).	33
Table 2: Scanning results and expected lamb production from mixed age ewes (Outcross trial year 1).	34
Table 3: Scanning results and expected lamb production from mixed age putative carrier and affected ewes (Pilot trial year 2).	35
Table 4: Scanning results and expected lamb production from ewe hoggets (Backcross trial year 2).	36
Table 5: Results (number of offspring in affected and unaffected categories) and chi square analysis of a cross between an affected ram and carrier ewes (Backcross trial year 2) .	37
Table 6: Concentration of undiluted samples from control and affected animal collagen extracts.	46
Table 7: Concentration of undiluted samples from control and affected animal proteoglycan extracts.	46

Table of contents

Acknowledgements	ii
Abstract	iii
Abbreviations.....	iv
List of figures	vi
List of table	vii
Table of contents	viii
1 – Introduction and review	1
1.1 Bone growth and development	1
1.2 Cartilage and skeletal dysplasias.....	2
1.3 Proteoglycans and skeletal dysplasias	2
1.3.1 Manganese, proteoglycans, and skeletal dysplasias.....	5
1.3.2 Chondroitin sulfate proteoglycans.....	6
1.3.3 Heparan sulfate proteoglycans.....	8
1.3.4 Sulfate metabolism, proteoglycans, and skeletal dysplasias	10
1.4 Collagen and skeletal dysplasia	14
1.4.1 Collagen type II.....	15
1.4.2 Collagen type IX.....	17
1.4.3 Collagen type X.....	18
1.4.4 Collagen type XI.....	19
1.5 Sheep chondrodysplasias.....	20
1.6 Texel chondrodysplasia.....	21
1.7 Research aims.....	27
2 – Breeding trial.....	29
2.1 Introduction.....	29
2.2 Materials and methods.....	29
2.2.1 Materials for breeding trial	29
2.2.2 Animals	30
2.2.3 Mating	30
2.2.4 Data recording	31
2.2.5 Sample collection	31
2.2.6 Chi squared analysis.....	31
2.3 Pilot trial (year one).....	32
2.3.1 Parturition	32
2.3.2 Chi square	33
2.4 Outcross trial (year one).....	34
2.4.1 Pregnancy scanning.....	34
2.4.2 Parturition	34
2.5 Pilot trial (year two)	35
2.5.1 Pregnancy scanning.....	35
2.5.2 Parturition	35
2.6 Backcross (year two)	36
2.6.1 Pregnancy scanning.....	36

2.6.2	Parturition	36
2.6.3	Chi square	37
2.7	Discussion	38
3	– Biochemical analysis of collagens and proteoglycans	41
3.1	Introduction	41
3.2	Materials and methods.....	42
3.2.1	Materials for collagen analysis	42
3.2.2	Guanidine hydrochloride extraction	42
3.2.3	Protein quantification	43
3.2.4	Polyacrylamide gel electrophoresis.....	44
3.3	Results.....	44
3.3.1	Protein quantification	44
3.3.2	Collagen SDS – PAGE.....	46
3.3.3	Proteoglycan SDS – PAGE.....	48
3.4	Discussion	49
4	– DNA analysis	56
4.1	Introduction.....	56
4.2	Materials and methods.....	56
4.2.1	Materials for DNA extraction and analysis	56
4.2.2	DNA extraction.....	57
4.2.3	Sample preparation.....	57
4.2.4	Phenol chloroform extraction	57
4.2.5	DNA extraction from blood.....	58
4.2.6	Oligonucleotides.....	58
4.2.7	Exon two polymerase chain reaction and sequencing primers.....	59
4.2.8	Exon three polymerase chain reaction and sequencing primers.....	59
4.2.9	General PCR reactions	60
4.2.10	Column purification of DNA.....	61
4.2.11	DNA Quantification	61
4.2.12	Restriction endonuclease digests.....	61
4.2.13	Agarose gel electrophoresis	62
4.2.14	DNA sequencing	62
4.2.15	Sequence analysis.....	62
4.3	PCR.....	63
4.3.1	Genomic DNA extraction	63
4.3.2	Exon 2	64
4.3.3	Exon 3	65
4.3.4	Diagnostic digest	66
4.3.5	DNA quantification	67
4.4	Sequence analysis.....	69
4.4.1	Exon 2	69
4.4.2	Exon 3	71
4.4.3	Overall exon alignment.....	73
5	– Summary and future direction	77
	Reference list.....	81
	Appendix A	91

Appendix B.....	93
Appendix C	94
Appendix D	95
Appendix E.....	98
Appendix F.....	101
Appendix G.....	104